编者按
作为全球肝病学领域最具影响力的学术盛会，美国肝病研究学会（AASLD）年会每年都汇聚着来自世界各地的顶尖专家与前沿成果。2026 年，随着 GLP-1 类药物重塑代谢相关脂肪性肝病（MASLD/MASH）治疗格局、乙肝功能性治愈曙光初现、人工智能（AI）与空间组学技术加速临床转化，肝病学正站在一个历史性的转折点上。
值此之际，《国际肝病》荣幸邀请到AASLD 现任主席——Saul J. Karpen教授，围绕本届大会的核心主题、从科研到临床的转化路径、AI 与新型生物标志物的突破，以及学会未来 3–5 年的全球战略展开深度对话。Karpen 教授强调，AASLD 的使命不仅是推动科学发现，更在于通过"一线临床医生教育计划"和"卓越肝脏网络"等创新举措，让前沿进展真正惠及每一位患者——无论其身在学术中心还是基层诊所。
洞见前沿：乙肝治愈、MASLD 与精准医疗
01
《国际肝病》：本届 AASLD 大会的核心主题有哪些？哪些领域的讨论最为引人注目？
Karpen教授：AASLD 2026大会全面展现了肝病学领域令人振奋的进展时期。今年年会的核心主题包括：乙肝功能性治愈的持续突破、MASLD 与 MASH 的新兴疗法（尤其是基于 GLP-1 的治疗方案）、肝癌与肝移植的创新进展，以及精准医学的深入应用。我们正见证一系列有望从根本上改变肝病预防、诊断和治疗方法的重要发展。
此外，大会还重点展示了用于加强肝病学家、高级医疗服务者以及——尤为值得关注的是——一线临床医生教育与培训的新产品与项目。
Hematology Digest： What are the core themes of this AASLD meeting? Which areas will be key discussion points?
Prof. Karpen: The Liver Meeting® 2026 highlights an exciting period of progress in hepatology. Major themes include advances toward a functional cure for hepatitis B, emerging therapies for MASLD and MASH, including GLP-1-based treatments, and innovations in liver cancer, transplantation, and precision medicine. We're seeing promising developments that could fundamentally change how we prevent, diagnose, and treat liver disease. We are also highlighting new products enhancing support for education and training of hepatologists, advanced practice providers and notably, frontline providers.
转化赋能：让前沿研究扎根临床实践
02
《国际肝病》：本次大会将如何助力将新研究转化为临床实践？是否有专门探讨真实世界挑战的环节？
Karpen教授：将科学发现转化为更优质的患者照护，是 AASLD 最重要的职责之一。今年的会议通过互动环节、专家讨论和以案例为基础的学习，着重强调了实践教育、更新的临床指南以及真实世界中的临床决策。
我们特别为全新的 "一线临床医生肝病照护计划"（Liver Care for Frontline Clinicians Program） 感到振奋，该计划旨在让初级保健医生更早参与肝病的筛查与更有效的管理。此外，AASLD 还公布了两项重大患者照护优化倡议："未来人才储备计划"（Workforce of the Future），致力于高级实践提供者的培训与教育；以及"卓越肝脏网络"（Liver Network of Excellence），旨在建立一个国家级的健康学习协作平台，用于实施临床实践指标。
我们的目标是确保研究进展能够以最快、最有效的方式惠及患者。
Hepatology Digest：How will this Congress help turn new research into clinical practice? Are there sessions addressing real-world challenges?
Prof. Karpen: One of AASLD's most important responsibilities is translating scientific discovery into better patient care. This year's meeting emphasizes practical education, updated clinical guidance, and real-world decision-making through interactive sessions, expert discussions, and case-based learning. We're particularly excited about our new Liver Care for Frontline Clinicians Program, which engages primary care providers in earlier detection and more effective management of liver disease. In addition, we have revealed plans from the AASLD to embrace optimization of patient care with two major initiatives: Workforce of the Future, that embraces advanced practice provider training and education, and the Liver Network of Excellence, to provide a national health learning collaborative for implementation of practice metrics.
Our goal is to ensure that advances in research reach patients as quickly and effectively as possible.
智领未来：AI 与生物标志物驱动个体诊疗
03
《国际肝病》：哪些突破性进展（如 AI 诊断和新生物标志物）尤为值得关注？它们可能产生怎样的影响？
Karpen教授：人工智能、先进诊断技术和新型生物标志物正在创造重要的机遇，使我们能够更早识别肝病并实现治疗个体化。我们看到有研究正在探索 AI 如何改善影像学、病理学及临床数据的解读，同时血液诊断标志物、创新方法（包括 RNA 编辑）也展现出巨大潜力。
这些进展有潜力增强临床决策能力、减少有创操作的依赖，并最终改善患者预后。当前的挑战在于证明这些创新如何在日常临床实践中被安全、有效地落地实施。特别是，这些进展将惠及 MASH、乙型肝炎、原发性胆汁性胆管炎（PBC）、原发性硬化性胆管炎（PSC）以及罕见肝病患者群体。
Hepatology Digest：What breakthroughs, such as AI diagnostics and new biomarkers, are particularly notable? What impact might they have?
Prof. Karpen: Artificial intelligence, advanced diagnostics, and new biomarkers are creating important opportunities to identify liver disease earlier and personalize treatment. We're seeing research exploring how AI can improve the interpretation of imaging, pathology, and clinical data, alongside promising blood-based diagnostics and innovative therapeutic approaches, including RNA editing. These developments have the potential to improve clinical decision-making, reduce reliance on invasive procedures, and ultimately improve patient outcomes. The challenge now is demonstrating how these innovations can be implemented safely and effectively in everyday clinical practice. In particular, these advances will help patients with MASH, Hepatitis B, PBC, PSC and rare liver disorders.
携手共进：全球协作与消除肝病使命
04
《国际肝病》：本次大会如何加强全球协作？未来 3–5 年 AASLD 将优先关注哪些方向？
Karpen教授：肝病是一项全球性健康挑战，有意义的进展离不开国际合作。今年的大会汇聚了来自 80 多个国家的参会者，为分享发现、建立合作伙伴关系以及缩小肝病诊疗差距创造了宝贵机会。
展望未来，AASLD 的关键优先事项包括：推动治疗创新、改善早期检测、加速病毒性肝炎消除、扩大循证照护的可及性，以及支持下一代肝脏研究人员和临床医生的发展。对科学的持续投入和全球协作，对于实现我们的最终使命——预防和治愈肝病——至关重要。
Hepatology Digest：How does this Congress strengthen global collaboration, and what will AASLD prioritize over the next three to five years?
Prof. Karpen: Liver disease is a global health challenge, and meaningful progress depends on international collaboration. This year's meeting brings together participants from more than 80 countries, creating opportunities to share discoveries, build partnerships, and address disparities in liver care. Looking ahead, key priorities for AASLD include advancing therapeutic innovation, improving early detection, accelerating viral hepatitis elimination, expanding access to evidence-based care, and supporting the next generation of liver researchers and clinicians. Continued investment in science and global collaboration will be essential to achieving our ultimate mission: preventing and curing liver disease.